JP2015524413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524413A5 JP2015524413A5 JP2015523255A JP2015523255A JP2015524413A5 JP 2015524413 A5 JP2015524413 A5 JP 2015524413A5 JP 2015523255 A JP2015523255 A JP 2015523255A JP 2015523255 A JP2015523255 A JP 2015523255A JP 2015524413 A5 JP2015524413 A5 JP 2015524413A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- amino acid
- acid sequence
- btnl3 protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 192
- 102100025430 Butyrophilin-like protein 3 Human genes 0.000 claims description 169
- 101000934741 Homo sapiens Butyrophilin-like protein 3 Proteins 0.000 claims description 169
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 129
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 79
- 229920001184 polypeptide Polymers 0.000 claims description 75
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 75
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 36
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 230000035755 proliferation Effects 0.000 claims description 20
- 238000012217 deletion Methods 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 238000003780 insertion Methods 0.000 claims description 19
- 230000037431 insertion Effects 0.000 claims description 19
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000005557 antagonist Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 9
- 230000001717 pathogenic effect Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000025020 negative regulation of T cell proliferation Effects 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 3
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 description 35
- 102000037865 fusion proteins Human genes 0.000 description 35
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 241000894007 species Species 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261673639P | 2012-07-19 | 2012-07-19 | |
| US61/673,639 | 2012-07-19 | ||
| PCT/US2013/051097 WO2014015148A1 (en) | 2012-07-19 | 2013-07-18 | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017210450A Division JP2018015009A (ja) | 2012-07-19 | 2017-10-31 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524413A JP2015524413A (ja) | 2015-08-24 |
| JP2015524413A5 true JP2015524413A5 (enExample) | 2016-07-14 |
| JP6448056B2 JP6448056B2 (ja) | 2019-01-09 |
Family
ID=48906512
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523255A Active JP6448056B2 (ja) | 2012-07-19 | 2013-07-18 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
| JP2017210450A Withdrawn JP2018015009A (ja) | 2012-07-19 | 2017-10-31 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
| JP2019228946A Withdrawn JP2020039369A (ja) | 2012-07-19 | 2019-12-19 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
| JP2021214198A Withdrawn JP2022040181A (ja) | 2012-07-19 | 2021-12-28 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
| JP2023192170A Withdrawn JP2023184751A (ja) | 2012-07-19 | 2023-11-10 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017210450A Withdrawn JP2018015009A (ja) | 2012-07-19 | 2017-10-31 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
| JP2019228946A Withdrawn JP2020039369A (ja) | 2012-07-19 | 2019-12-19 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
| JP2021214198A Withdrawn JP2022040181A (ja) | 2012-07-19 | 2021-12-28 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
| JP2023192170A Withdrawn JP2023184751A (ja) | 2012-07-19 | 2023-11-10 | ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20150166630A1 (enExample) |
| EP (1) | EP2875046B2 (enExample) |
| JP (5) | JP6448056B2 (enExample) |
| CN (1) | CN104703999A (enExample) |
| AU (3) | AU2013292510A1 (enExample) |
| MX (1) | MX366178B (enExample) |
| WO (1) | WO2014015148A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2221063A1 (en) * | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
| MX2011008430A (es) | 2009-02-20 | 2011-09-29 | Ganymed Pharmaceuticals Ag | Metodos y composiciones para diagnostico y tratamiento del cancer. |
| EP3689911B1 (en) | 2009-11-11 | 2024-08-21 | Astellas Pharma Inc. | Antibodies specific for claudin 6 (cldn6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| EP3026064B1 (en) | 2011-05-13 | 2018-10-17 | Ganymed Pharmaceuticals GmbH | Antibodies for treatment of cancer expressing claudin 6 |
| US20150166630A1 (en) * | 2012-07-19 | 2015-06-18 | Amgen Inc. | Btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| CN107630085B (zh) * | 2017-10-12 | 2020-09-29 | 王丽 | 分子标志物在男性骨质疏松中的应用 |
| CN113227127A (zh) * | 2018-06-05 | 2021-08-06 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| BR112021013193A2 (pt) | 2019-01-07 | 2021-09-28 | Shattuck Labs, Inc. | Proteínas heterodiméricas para modulação de células t gama delta |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| WO1999031241A1 (en) | 1997-12-17 | 1999-06-24 | Immunex Corporation | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| CA2350417C (en) | 1998-12-02 | 2010-02-09 | Bristol-Myers Squibb Company | Dna-protein fusions and uses thereof |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US6699473B2 (en) | 2000-10-13 | 2004-03-02 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| EP1585760B1 (en) | 2002-12-23 | 2012-08-08 | Immunex Corporation | Btl-ii nucleic acids, proteins, and antibodies |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| EP1702622A1 (en) * | 2005-03-18 | 2006-09-20 | CONARIS research institute AG | Soluble BTNL2 protein useful to inhibit inflammatory disorders |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| EP2052088A2 (en) | 2006-08-02 | 2009-04-29 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2221063A1 (en) * | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
| WO2011127418A1 (en) | 2010-04-09 | 2011-10-13 | Amgen Inc. | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| US20150166630A1 (en) * | 2012-07-19 | 2015-06-18 | Amgen Inc. | Btnl3 proteins, nucleic acids, and antibodies and uses thereof |
-
2013
- 2013-07-18 US US14/407,904 patent/US20150166630A1/en not_active Abandoned
- 2013-07-18 EP EP13742802.5A patent/EP2875046B2/en active Active
- 2013-07-18 MX MX2015000754A patent/MX366178B/es active IP Right Grant
- 2013-07-18 AU AU2013292510A patent/AU2013292510A1/en not_active Abandoned
- 2013-07-18 CN CN201380038216.0A patent/CN104703999A/zh active Pending
- 2013-07-18 JP JP2015523255A patent/JP6448056B2/ja active Active
- 2013-07-18 WO PCT/US2013/051097 patent/WO2014015148A1/en not_active Ceased
-
2017
- 2017-10-31 JP JP2017210450A patent/JP2018015009A/ja not_active Withdrawn
-
2018
- 2018-01-09 AU AU2018200171A patent/AU2018200171A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/256,951 patent/US11459370B2/en active Active
- 2019-10-16 AU AU2019250154A patent/AU2019250154B2/en active Active
- 2019-12-19 JP JP2019228946A patent/JP2020039369A/ja not_active Withdrawn
-
2021
- 2021-12-28 JP JP2021214198A patent/JP2022040181A/ja not_active Withdrawn
-
2022
- 2022-08-23 US US17/893,998 patent/US20230192802A1/en not_active Abandoned
-
2023
- 2023-11-10 JP JP2023192170A patent/JP2023184751A/ja not_active Withdrawn
-
2025
- 2025-03-28 US US19/094,506 patent/US20250361283A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102223873B1 (ko) | 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용 | |
| JP2016505635A5 (enExample) | ||
| CN111533809A (zh) | 针对新型冠状病毒的亚单位疫苗及应用 | |
| JP2019511222A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2013516456A5 (enExample) | ||
| TW202206097A (zh) | 冠狀病毒抗原組成物及其用途 | |
| JP2020528744A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2015500811A5 (enExample) | ||
| JP2011520783A5 (enExample) | ||
| CN101678092B (zh) | 核酸 | |
| JP2013518599A5 (enExample) | ||
| Olga et al. | Nanobodies are potential therapeutic agents for the Ebola virus infection | |
| JP2015511599A5 (enExample) | ||
| WO2024226829A2 (en) | Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer | |
| WO2022127825A1 (zh) | 针对新型冠状病毒感染的疫苗组合物 | |
| JP2023527918A5 (enExample) | ||
| CN102178950B (zh) | 一种亚单位疫苗免疫佐剂及应用 | |
| CN119923271A (zh) | 包含结核病抗原的疫苗构建体 | |
| CN106543287A (zh) | 构象表位疫苗和应用 | |
| CN108059685A (zh) | 猪口蹄疫病毒A型Fc多肽疫苗及其制备方法和应用 | |
| Kumar et al. | Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster |